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Abstract
Background: The survival of patients with locally advanced head and neck cancer is still poor, with 5-year survival rates
of 24–35%. The identification of prognostic and predictive markers at the molecular and cellular level could make it
possible to find new therapeutic targets and provide "taylor made" treatments. Established cell lines of human squamous
cell carcinoma (HNSCC) are valuable models for identifying such markers.
The aim of this study was to establish and characterize a series of cell lines and to compare the cisplatin sensitivity and
18F fluoro-2 deoxy 2 glucose (18F-FDG) uptake of these cell lines with other cellular characteristics, such as proliferation
parameters and TP53 and CCND1 status.
Methods: Explant cultures of fresh tumour tissue were cultivated, and six new permanent cell lines were established
from 18 HNSCC cases. Successfully grown cell lines were analysed regarding clinical parameters, histological grade,
karyotype, DNA ploidy, and index and S-phase fraction (Spf). The cell lines were further characterized with regard to
their uptake of 18F-FDG, their sensitivity to cisplatin, as measured by a viability test (crystal violet), and their TP53 and
CCND1 status, by fluorescence in situ hybridization (FISH), polymerase chain reaction single-strand conformation
polymorphism (PCR-SSCP) with DNA sequencing and, for cyclin D1, by immunohistochemistry.
Results: Patients with tumours that could be cultured in vitro had shorter disease-free periods and overall survival time
than those whose tumours did not grow in vitro, when analysed with the Kaplan-Meier method and the log-rank test.
Their tumours also showed more complex karyotypes than tumours from which cell lines could not be established. No
correlation was found between TP53 or CCND1 status and 18F-FDG uptake or cisplatin sensitivity. However, there was
an inverse correlation between tumour cell doubling time and 18F-FDG uptake.
Conclusion: In vitro growth of HNSCC cells seem to be an independent prognostic factor, with cell lines being more
readily established from aggressive tumours, a phenomenon more dependent on the molecular genetic characteristics of
the tumour cells than on tumour location or TNM status.
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Table 1: The characteristics of the primary tumours regarding clinical data, DNA content and cytogenetics.
Tumour Take Rate Corresponding 
cell line name
Site T_ stage N_ stage M_ stage Stage Grade Flowcyto 
Metry
DNA _indices Cytogenetics
1 yes LU-HNxSCC-3 310 4 0 0 4 G3 diploid 1 not complex
2 yes LU-HNxSCC-6 021 3 0 0 3 G3 nondiploid 1,25 complex
3 yes LU-HNxSCC-8 060 2 1 0 3 G3 nondiploid 1,9 complex
4 yes LU-HNxSCC-4 040 2 0 0 2 G3 nondiploid 1,85 complex
5 yes LU-HNxSCC-5 062 2 2b 0 4 G2 nondiploid 2,38 complex
6 yes LU-HNxSCC-7 060 2 0 0 2 G2 diploid 1 complex
7 no 021 2 0 0 2 G2 nondiploid 1,9 failure
8 no 119 1 0 0 1 G3 nondiploid 1,22 failure
9 no 321 3 1 0 3 G3 diploid 1 not complex
10 no 040 2 2c 0 4 G2 nondiploid 1,87 complex
11 no 090 3 0 0 3 Gx diploid 1 failure
12 no 322 4 0 0 4 G2 nondiploid 1,93 failure
13 no 119 2 2a 0 4 G4 diploid 1 failure
14 no 139 2 2c 0 4 G2 nondiploid 1,28 missing
15 no 321 4 2b 0 4 G3 nondiploid 1,59 complex
16 no 320 4 0 0 4 G2 diploid 1 failure
17 no 770 0 2b 0 4 G2 nondiploid 1,51 failure
18 no 040 1 2a 0 4 G2 diploid 1 complexJournal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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Background
In 2006, 101,600 new cases and 42,400 deaths resulting
from oropharyngeal cancer were registered in Europe [1].
Although morbidity has decreased, the outcome of
patients with locally advanced head and neck cancer is
still poor, 5-year survival rates being only 24–35% [2,3].
There is a need for more individualized, "taylor-made"
therapies in order to avoid under-treatment (residual dis-
ease) as well as over-treatment (unnecessary morbidity).
The application of new techniques has improved our
understanding of the mechanisms behind the origin,
maintenance and progression of tumours, and new
insights have facilitated the identification of diagnostic,
prognostic and predictive markers at molecular and cellu-
lar levels, paving the way for novel therapeutic
approaches.
Cell lines of human squamous cell carcinoma are valuable
models for identifying such markers, and for studies of
tumour biology. In this study, explant cultures of fresh
tumour tissue were cultivated and six new permanent cell
lines were established from 18 patients with head and
neck squamous cell carcinoma (HNSCC). The cell lines
established in this study were used to test for cisplatin sen-
sitivity, 18F-FDG uptake, as a measure of metabolic activ-
ity, and various other tumour characteristics.
Methods
Patients
Fresh tumour samples were collected during 1995–1999
from 18 patients with HNSCC. The patients participated
voluntary and with informed consent. Seventeen of the 18
patients with HNSCC were previously untreated and one
patient had a residual tumour after radiotherapy. Eight
tumours were located in the oral cavity, four in the larynx,
two in the nasopharynx, and one each in the oropharynx,
hypopharynx and in the maxillary sinus. One was an
untreated lymph node metastasis of unknown primary
origin. Table 1 shows the tumour TNM (Tumour, Node,
Metastasis) classification, stage, grade, ploidity and karyo-
type of each tumour. Permanent cell lines were success-
fully established from the first six tumours in Table 1; four
were from the oral cavity, one from the maxillary sinus
and one was a residual tumour from the oral cavity. Table
2 shows clinical information regarding treatment regim,
survival data and causes of death.
Establishment of cell lines
Fresh tumour tissue samples obtained during surgery were
immersed immediately in buffered balanced saline. The
tissues were washed several times, trimmed and minced
into 1 to 2 mm pieces, which were placed in T25 tissue
culture flasks with DMEM supplemented with 2 mM L-
glutamine and 10% foetal bovine serum (FBS). The flasks
were incubated at 37°C in an atmosphere containing 5%
carbon dioxide. Primary tissue culture flasks were
observed daily. To reduce the fibroblast growth, DMEM
D-valine was added instead of L-valine. Fibroblasts were
also removed mechanically and by brief exposure to
trypsin (0.1%) and EDTA (0.02%). Tumour cells were
subcultured when the flasks were 50% confluent. After
three or four passages the cells were stored in liquid nitro-
gen. Low passage numbers (<30) were used for this study.
Growth characteristics
The cell lines were denoted LU-HNSCC 3 to 8. All cell
lines had an epitheloid appearance, and grew in a typical
cobblestone pattern indicating squamous cell carcinoma
origin. The cells differed in size and grew in colonies with
cell-to-cell contact into confluence. All cell lines, besides
number 6, grew as monolayer cultures and were easy to
detach using trypsin; cells from LU-HNSCC 6 were more
difficult to detach and to grew in multiple layers.
Growth rate
To determine the in vitro tumour cell growth rate, 15,000–
100,000 cells were plated in Petri dishes, and the number
of cells was counted every second day in a Bürker cham-
ber. The growth rate for each cell line was determined at
least twice and the results were found to be reproducible.
The mean values of 2–5 samples were estimated. The dou-
bling times were derived from the exponential growth
phase, and are given in Table 3, together with other data.
Tumorigenicity in nude mice
To verify the malignancy of the established cell lines in
vitro, a cellsolution containing the same cell amount from
each cell line were injected subcutaneously into the lateral
thoracic wall of nude mice. Tumour formation was
observed for all cultured cell lines. The purpose of this
experiment was to confirm the malignant characteristics
of the cultured cell lines and to exclude a fibroblast cell
population. The tumour formations in nude mice were no
further examined in this experiment. The study was
approved by the Regional Ethics Board of Southern Swe-
den Committe(LU376-01, M48-06).
Flow cytometry
Frozen samples from 16 biopsies from primary tumours
were analysed, and two samples from formalin-fixed and
paraffin-embedded specimens were also analysed. Flow
cytometry DNA analysis was performed as previously
described [4]. Briefly, the tumour samples were minced,
forced through a nylon net (pore size 140 μm, Tidbeck
AB, Stockholm, Sweden), and fixed in 70% ethanol. The
two formalin-fixed samples were processed to form cell
suspensions according to a previously described method
[5].Journal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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The separated cells were then treated with ribonuclease
(Sigma-Aldrich, Stockholm, Sweden), incubated with
pepsin (Merck, Darmstadt, Germany), and stained with
propidium iodide (Sigma-Aldrich, Stockholm). Human
lymphocytes were processed in parallel with the tumour
samples and used as an external diploid control for the
fresh samples. Flow cytometric DNA analysis was per-
formed in a FACS Caliber (Becton, Dickinson, BD Bio-
sciences, USA). Up to 20,000 nuclei were analysed from
each sample. The DNA histograms obtained were auto-
matically processed using Modfit LT 3.1™ software. The
DNA index (DI) was calculated as the ratio of the modal
channel values of the G0 and G1 peaks. By definition, the
tumours manifesting a single DNA population were clas-
sified as diploid (i.e. DI = 1.00), and tumours manifesting
two or more populations as non-diploid. The S-phase
fraction (Spf) was estimated assuming that the S-phase
compartment constituted a rectangular distribution
between the modal values of the G0/G1 and G2 peaks.
Chromosome banding analysis
Fresh samples from all but one of the 18 primary tumours
previously had been subjected to short-term culturing and
G-banding analysis [6]. All six established cell lines were
also cytogenetically analysed using the same methods as
in the present study.
Table 2: The features of the primary tumours regarding treatment regime, follow up time and cause of death.
Tumour Take 
Rate
Corresponding 
cell line
Site Surgery Radiation-
therapy
Disease free 
months
Overall 
survival In 
months
Death caused 
by intercurrent 
disease
Death 
caused by 
HNSCC
1 yes LU-HNxSCC-3 310 No Yes 0 12 No Yes
2 yes LU-HNxSCC-6 021 Yes Yes 6 8 no Yes
3 yes LU-HNxSCC-8 060 Yes Yes 2 4 Yes No
4 yes LU-HNxSCC-4 040 Yes Yes 37 42 yes No
5 yes LU-HNxSCC-5 062 No Yes 4 4 No Yes
6 yes LU-HNxSCC-7 060 Yes yes 19 25 no Yes
7n o 0 2 1 Y e s N o 0 1 Y e s N o
8n o 1 1 9 N o Y e s 2 5 4 3 N o Y e s
9 no 321 No No 0 1 No Yes
10 no 040 Yes Yes 74 96 No Yes
11 no 090 No Yes 99 108 No No
12 no 322 Yes Yes 85 87 Yes No
13 no 119 No Yes 90 108 No No
14 no 139 No Yes 0 78 No Yes
15 no 321 Yes Yes 66 75 No Yes
16 no 320 Yes Yes 8 1 Yes No
17 no 770 Yes Yes 113 122 No No
18 no 040 yes yes 98 108 no noJournal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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Immunohistochemistry
Immunohistochemical (IHC) analysis was performed on
paraffin-embedded specimens to detect cyclin D1
(CCND1) expression. A commercial monoclonal anti-
body (NCL-cyclin D1, Novo) was used at a dilution of
1:20. A specimen known to be strongly positive, previ-
ously collected from a patient, was used as a positive con-
trol. The IHC results were scored as follows: A-negative; B
1–5% of the tumour cells positive; C 6–50% positive; D
>50% positive. The negative controls were tested without
primary antibodies.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
as previously described [7], with minor modifications.
Briefly, tumour cells were spread onto Superfrost Plus
slides (Menzel, Braunschwieg, Germany), and then air
dried and fixed in a series of 50, 75 and 100% Carnoy's
solution (100% Carnoy's = 3:1 methanol:acetic acid).
Prior to hybridization, the slides were denatured in 70%
formamide, 2 × SSC, pH 7.0, at 72°C for three minutes,
and dehydrated in a series of ethanol solutions (70, 85
and 100%). Two-colour FISH was performed with directly
labelled probes for CCND1 and the centromere of chro-
mosome 11 (LSI Cyclin D1 spectrum orange TM/CEP 11
spectrum green TM DNA Probe; Vysis, Inc., Downers
Grove, IL, USA). Slides were counterstained with 0.2 mM
4,6-diamidino-2-phenylindole in an antifade solution
(Vectashield, Vector H1000; Vector Laboratories, Burlin-
game, CA, USA) in order to visualize the nuclei and to pre-
vent the fluorochromes from fading. A Zeiss Axioplan 2
microscope (Carl Zeiss AG, Oberkochen, Germany),
equipped with a cooled CCD camera (Sensys; Photomet-
rics, Tucson, NV, USA), operated by Quips FISH image
analysis software (Vysis, Inc.) was used to analyse the
samples. Hybridization signals from at least 50 nuclei
were scored to assess the centromere and CCND1 copy
numbers. The nuclei were defined as carrying an amplifi-
cation if the number of gene probe signals divided by the
number of centromere signals was ≥ 1.5.
PCR-SSCP and DNA sequencing
Polymerase chain reaction-single-strand conformation
polymorphism (PCR-SSCP) analysis and DNA sequenc-
ing were used to study the occurrence of mutations in
exons 4–11 of TP53, as previously described [8]. Briefly,
DNA was extracted using standard methods and used in a
polymerase chain reaction to amplify the entire coding
region of the TP53 gene in seven or eight different frag-
ments. The PCR products were screened for mutations
using SSCP. Samples showing altered mobility shift in
SSCP were further analysed with direct DNA sequencing
to determine the exact location and type of mutation.
Cisplatin-induced cell death
The cell lines LU-HNSCC 3–8 were harvested by trypsini-
zation, counted and seeded (10,000–26,000 cells/well) in
24-well plates, and allowed to grow for two days as mon-
olayer cultures in DMEM medium (GIBCO, San Diego,
CA, USA), supplemented with 10% FBS and antibiotics
(100 U/ml streptomycin sulphate, GIBCO), under a 5%
CO2 atmosphere at 37°C. On day two, cisplatin (Pharma-
link AB, Upplands Väsby, Sweden) was added in serum-
free medium, and the cells were incubated for 1 h at con-
centrations ranging from 0 to 100 μM. Thereafter, the
drug-containing medium was removed, and cells were
allowed to grow in drug-free medium for 5 days. On day
7, the cell viability was estimated by the crystal violet
assay, as described previously [9]. Briefly, the cells were
incubated with 0.5% crystal violet (methanol:water,1:4)
and excess dye was removed. The cells were solubilized by
the addition of 0.10 M citrate buffer (SIGMA) (50% (v/v)
ethanol) and then transferred to a new 96-well plate, and
the absorbance was determined spectrophotometrically at
570 nm on a Multiscan MS (Labsystems, Finland) and
corrected for background absorbance.
18F-FDG measurements
The established cell lines LU-HNSCC 3–8 were harvested
by trypsinization, counted and seeded (50,000–250,000
cells/Petri dish) on day 0. The cells were allowed to grow
for two days as monolayer cultures in DMEM
medium(GIBCO, San Diego, CA) supplemented with
10% heat-inactivated FBS containing an antibiotic
(GIBCO)(100 U/ml streptomycin sulphate), under a 5%
CO2 atmosphere at 37°C. On day three, 2 ml 18F-FDG
solution (0.62–1.33 MBq/ml) was added. After an hour
Table 3: Characteristics of the established cell lines regarding 
cisplatin sensitivity and cell doubling time.
Cell line Name Cisplatin IC50 Cell doubling time
LU-HNxSCC (μM) * (Days) **
3 24,8 ± 6,4 1,8 ± 0,4
4 6 ± 0,9 1,1 ± 0,1
5 29,2 ± 3,1 1,6 ± 0,2
6 16,5 ± 4,5 1,3 ± 0,4
7 11,3 ± 3,5 2,2 ± 0,2
8 9,3 ± 3,1 1,4 ± 0,3
* cisplatin sensitivity is the mean of 3–6 experiments ± SEM and 
studied passage number 10–30
** cell doubling time is the mean values from two or more 
experiments and studied passage number 5–26Journal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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the solution was removed by aspiration. The Petri dishes
with cells were rinsed three times with PBS. The cells were
then harvested from the Petri dishes by trypsinization and
neutralized with 4 ml medium, and collected as samples
for 18F-FDG determination together with the discarded
18F-FDG solution.
The 18F-FDG uptake in the cells and in the washing frac-
tions was estimated using a calibrated 3 x 3 inch NaI(TI)
well counter (in house) (1282 CompuGamma CS, LKB
Wallac, Turku, Finland) and all 18F-FDG values were nor-
malized for time. Electronic cell counting was performed
using a NucleoCounter™ (Chemotec A/S, Allerod, Den-
mark) with the NucleoView™ software. The total cell con-
tent and number of viable cells were calculated per ml and
correlated to the 18F-FDG uptake corrected for decay. This
experiment was repeated in a second series.
Statistics
Descriptive statistics, Fisher's exact test, and the chi-
squared test for trend, were used to evaluate differences in
clinical parameters between patients whose tumours
could be cultured, and those that could not. Disease-free
periods and overall survival time in these groups were
examined using Kaplan-Meier graphs and log-rank tests
(SPSS for Windows version 14.0, Chicago, IL, USA). The
degree of linear relationship between pairs of variables
measured on a continuous scale was summarized using
correlation (r) and a test for zero slope in a corresponding
linear regression model. Kruskal-Wallis' test was used to
test the null hypothesis of equal cisplatin sensitivity for
the cell lines. For comparison of 18F-FDG uptake between
the cell lines, the following multiple linear regression
model was used:
FDG = c1 + b1V + c2I2 + b2I2V + c3I3 + b3I3V + c4I4 + b4I4V + 
c5I5 + b5I5V + c6I6 + b6I6V
where the dependent variable 18F-FDG is 18F-FDG
uptake and the independent variables are:
V = Number of viable cells
five dummy variables contrasting cell lines 2–6 to cell line
1:
Ij = 1 if cell line = j, j = 2–6
Ij = 0 otherwise
and five interaction parameters (products):
IjV = V if cell line = j, j = 2–6
IjV = 0 otherwise
This linear model has 12 parameters with the following
interpretation:
c1: Intercept for the reference cell line (1)
b1: Slope for the reference cell line (1)
cj: Intercept difference between cell line j and the reference
cell line, j = 2–6
bj: Slope difference between cell line j and the reference
cell line, j = 2–6
In this modelling framework, an F-test was used to test the
null hypothesis of equal 18F-FDG uptake for the cell lines
at a fixed number of viable cells. The packages SPSS 14.0
(Chicago, IL, USA) and Stata 10.0 (StataCorp 2007, Col-
lege Station, TX, USA) were used for statistical analysis.
Results
Patients: primary tumour characteristics and clinical 
course
Six new permanent squamous cell carcinoma lines in vitro
were established from 18 HNSCCs, which constitutes an
overall success rate of 33%.
The overall survival of the patients as a function of the
propensity of their tumours to grow in vitro, calculated
from date of diagnosis, is shown in Figure 1. The outcome
for the patients from whom cell lines could be established
was worse than for the other patients; the median overall
survival being 8 vs. 78 months (p = 0.009;logrank test),
and the fraction of 5-year survival 0 vs. 67%. The mean
disease-free survival time was 13 months for the patients
whose tumours grew as cell lines, compared with 80
months for those whose cancers did not grow in vitro (p =
0.056). No differences were observed in the two groups
regarding tumour site, TNM status, stage, grade, ploidity
or DNA indices (data not shown).
Chromosome banding analysis
Five of the six tumours that grew as cell lines had complex
karyotypes, defined here as at least three different aberra-
tions, when examined after short-term culturing. In con-
trast, only three of the 11 tumours from which no cell line
could be established, and from which material had been
sent for short-term culturing, had complex karyotypes.
The remaining eight cases either failed to grow in vitro
(seven cases), or showed an abnormal karyotype with
simple changes (one case). There was no aberration in
common among the tumours that yielded viable cell
lines, and it was noted that none of them displayed
homogeneous staining regions. Only minor changes were
noted when comparing the karyotypes obtained afterJournal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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short-term culturing of primary tumours and in the corre-
sponding cell lines (data not shown).
The established cell lines
Three cell lines showed TP53 mutations, two in exon 7
and one in exon 5 (Table 4). Two of the mutations, one in
exon 5 and one in exon 7, were missense mutations, and
one in exon 7 was a deletion. Two of the three cell lines
with TP53 mutation also showed CCND1 overexpression;
one of these had CCND1 amplification according to FISH.
No cell line showed CCND1 amplification without TP53
mutation.
18F-FDG uptake
The 18F-FDG uptake, expressed as counts per minute
(cpm) adjusted for time, was strongly correlated with the
number of viable cells present, as illustrated in Figure 2.
The correlations varied between 0.94 (LU-HNSCC 3) and
0.99 (LU-HNSCC 7). The null hypothesis of no difference
in 18F-FDG uptake between the cell lines was evaluated in
a linear regression framework (see Statistics) and accord-
ing to this model, the predicted 18F-FDG uptake for
1,000,000 viable cells varied more than a factor 2, from
65,000 cpm for LU-HNSCC 3 to 133,000 cpm for LU-
HNSCC 6. The null hypothesis of equal 18F-FDG uptake
for this fixed number of viable cells could be rejected (p <
0.0001; F-test). Significant differences in 18F-FDG uptake
between the cell lines (p < 0.01) was seen for all reference
values from 50,000 to 1,500,000 viable cells and also in
sub-group analyses excluding one of the two cell lines
with non-overlapping ranges for number of viable cells.
No correlation was observed between 18F-FDG uptake or
gene expression and cell characteristics, such as TP53 and
CCND1 status or DNA ploidity.
Overall survival of the patients stratified by propensity of their tumours to grow in vitro Figure 1
Overall survival of the patients stratified by propensity of their tumours to grow in vitro. Survival times were cal-
culated from date of diagnosis. Four patients were still alive (survival >100 months) when this analysis was carried out.Journal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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We found an inverse correlation (r = -0.82) between cell
doubling time (DT) and 18F-FDG uptake; the shorter the
doubling time, the higher the 18F-FDG uptake (p = 0.04;
test for zero slope in a linear regression of predicted 18F-
FDG uptake at 1,000,000 viable cells on doubling time; n
= 6).
This inverse relationship was even stronger if the cell line
LU-HNSCC 3 with no observations above 600,000 viable
cells was omitted (r = -0.95; p = 0.01) or if the cell line LU-
HNSCC 7 with no observations below 700,000 viable
cells was omitted and the 18F-FDG uptake was predicted
for 500,000 viable cells (r = -0.96; p = 0.01). The experi-
ment was repeated with similar results.
In brief, the correlations between 18F-FDG uptake and
number of viable cells varied from 0.81 to 0.98 and the
predicted 18F-FDG uptake at 1,000,000 viable cells varied
significantly between the cell lines also in the second
experiment (p < 0.0001). Also the negative correlation
between 18F-FDG uptake and DT was reproduced in the
second series (r = -0.70; p = 0.12; n = 6). By combining the
data from the two experiments, the p-value for the inverse
correlation between 18F-FDG uptake and DT dropped to
0.004.
Cisplatin sensitivity
The cisplatin sensitivity of the different cell lines is illus-
trated in Figure 3. Significant differences in cisplatin sen-
sitivity between the cell lines was seen at 5, 50 and 100 μM
(p < 0.0001; Kruskal-Wallis test). The values of IC50 for the
different cell lines varied between 6 and 29 μM. The cispl-
atin sensitivity did not show any relationship with TP53
mutations, CCND1  amplification or overexpression, or
tumour doubling time.
Discussion
In accordance with other studies [10-12], we found that
tumours that could grow in vitro were more aggressive in
their biological behaviour, with shorter patient disease-
free periods and overall survival time, compared with
those that did not grow in vitro. No correlation was found
between ability to grow and clinical parameters such as
TNM status, or tumour grade or site. In agreement with
our results, Kim et al. established nine new permanent
SCC cell lines, but their propensity to grow in vitro did not
appear to be related to tumour site or grade [13]. Thus, in
vitro growth, in the present study seems to be an inde-
pendent prognostic factor, in concordance with other
authors [10-12] although there also are reports on lack of
such correlation [14]. The capacity of tumour cells to grow
in vitro could be dependent on their genetic alterations.
Support for this hypothesis comes from the finding that
all the culturable cell lines, except for one in this study
were seen to have complex karyotypes after short-term
culturing. Additionally, complex karyotypes have been
shown to be associated with poor prognosis [15].
We also investigated possible differences between the two
tumour groups regarding DNA content, index and S-phase
fraction, but no statistically significant differences were
found. These cellular characteristics have been widely
investigated previously, since they are assumed to reflect
the loss of normal cell proliferation control and the
underlying genetic abnormalities. The prognostic value of
DNA content is, however, more uncertain. While some
studies have found a correlation with poor outcome and
higher recurrence rate in aneuploid tumours [16,17], the
opposite, i.e. better survival of those with non-diploid
tumours, has also been reported [18].
Table 4: Characteristics of the established cell lines regarding proliferation parameters, DNA content and gene expression.
Cell line Flowcytometry
(n = 1)
Immunohistochemistry
(n = 3)
PCR_SSCP
(n = 1)
FISH
(n = 1)
Cytogenetics
(n = 1)
LU-HNxSCC Ploidity DNA indices S%phase Cyclin D1 Tp53 Cyclin D1
3 Diploid (p4) 1 ND* A 0 0 not complex
4 Nondilploid (p22) 1,4 26,3 C exon7 R249G 0 complex
5 Nondiploid (p27) 2,1 23,8 D exon5 H168P ++ complex
6 Nondiploid (p20) 1,2 16 A 0 0 complex
7 Nondiploid (p6) 1,4 9,8 A 0 deletion complex
8 Nondiploid (p22) 1,6 22,2 B(1/3C) exon7 Ldel252 1/3+ complex
* ND = not determinedJournal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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The extent of 18F-FDG uptake has been suggested to pro-
vide a measure of tumour aggressiveness, and thus to be
associated with poor prognosis in many tumour types
[19,20], including HNSCC [21,22]. The usefulness of 18F-
FDG-PET in HNSCC for detection of recurrent disease is
well recognized and clinical studies have shown a capacity
for PET to predict response to cytotoxic therapy [23,24].
We determined the 18F-FDG uptake and its relation to
cell viability in the established cell lines and found an
inverse correlation between cell doubling time (DT) and
18F-FDG uptake; the shorter the doubling time, the
higher the 18F-FDG uptake. The correlation between the
number of viable cells and 18F-FDG uptake, and between
a shorter tumour doubling time and a higher 18F-FDG
uptake, support a relation between 18F-FDG metabolism
and tumour aggressiveness. A similar correlation between
18F-FDG uptake and cell proliferation has been described
for other cancer types, including breast and colonic
tumours [25]. In another in vitro study using HNSCC
lines, Minn et al.[26] found a relation between 18F-FDG
uptake and cell proliferation index, defined as the per-
centage of tumour cells in the S+G2/M phase, while Smith
et al.[27] found a similar correlation with the S-phase frac-
tion. Furthermore, in a clinical trial on 14 patients, a close
correlation between growth fraction, determined by Ki67-
MIB-1, and PCNA, assessed with immunohistochemistry,
and 18F-FDG uptake was demonstrated [28], but no cor-
relation between 18F-FDG uptake and DNA ploidity was
seen. The close relation between CCND1 status and cell
proliferation suggests that deregulated CCND1 could be a
factor affecting 18F-FDG uptake. However, we found no
correlation between cyclin D1 expression or CCND1
amplification and 18F-FDG uptake. Similar results, i.e. no
correlation between CCND1 status and 18F-FDG uptake,
have been reported in a clinical trial on lung cancer
patients [29].
The 18F-FDG uptake, expressed as counts per minute adjusted for time, versus number of viable cells present for the six cell  lines, scatter plot and fitted regression lines Figure 2
The 18F-FDG uptake, expressed as counts per minute adjusted for time, versus number of viable cells present 
for the six cell lines, scatter plot and fitted regression lines.Journal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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Some studies have found TP53 mutations to be accompa-
nied by increased glycolysis, which could be the result of
reduced synthesis of proteins in the COX ∏ subunit or
increased transcription of HK-2 [30,31]. We found no
association between the presence or absence of TP53 and
increased 18F-FDG uptake.
To best of our knowledge, there are no previous reports on
possible correlations between 18F-FDG uptake and
CCND1 or TP53 status in HNSCC, although similar stud-
ies have been carried out on other tumours [29,30], dem-
onstrating a correlation between TP53 overexpression and
higher 18F-FDG uptake [30]. One reason why we did not
observe any correlation between the 18F-FDG uptake and
the TP53 and CCND1 status could be that the tumour
cells in vitro have an excess of nutrients, and that they must
be placed under stress to reveal a correlation. Therefore,
the next experimental step will be to treat the cell lines
with cisplatin, perhaps providing more insight into the
complex and still enigmatic mechanisms behind the intra-
cellular uptake and accumulation of 18F-FDG.
The six cell lines were also tested regarding cisplatin sensi-
tivity. Cisplatin-induced cell death was measured using
crystal violet staining, a method evaluated before [9]. A
statistical difference was found between the cell lines,
demonstrating the usefulness of the model for studying
chemosensitivity.
Conclusion
The results in this present study support the value of
tumour cell cultures as a model for prognostic and predic-
tive studies. We found the successful establishment of an
in vitro cell line from a tumour to be an independent neg-
ative prognostic marker. Furthermore, we found it feasible
to study metabolic activity with 18F-FDG uptake, and
Survival curves of the different cell lines exposed to varying concentrations of cisplatin obtained by crystal violet assay Figure 3
Survival curves of the different cell lines exposed to varying concentrations of cisplatin obtained by crystal vio-
let assay. Each value represents an average of at least three experiment.Journal of Experimental & Clinical Cancer Research 2009, 28:17 http://www.jeccr.com/content/28/1/17
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other tumour biologic characteristics, including the chem-
osensitivity of the cell lines. Despite the relatively small
number of tumour lines, we found a statistically signifi-
cant correlation between a shorter tumour doubling time
and higher 18F-FDG uptake. However, no significant dif-
ference was seen between 18F-FDG uptake and other pro-
liferation parameters, including TP53 and CCND1 status.
Although, the complex metabolic interactions between
host and tumour, which create the microenvironment in
vivo, will not be reproducible in cultured cell lines the
growing knowledge of tumour cell characteristics will pro-
vide more understanding of the clinical behaviour of
HNSCC tumours and of prognosis and therapy results for
HNSCC patients.
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